Baseline Characteristics of the VANISH Cohort.
Adolescent
Adult
Angiotensin II Type 1 Receptor Blockers
/ adverse effects
Brazil
Canada
Cardiomyopathy, Hypertrophic
/ diagnosis
Child
Denmark
Disease Progression
Double-Blind Method
Female
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Mutation
Phenotype
Recovery of Function
Sarcomeres
/ genetics
Time Factors
Treatment Outcome
United States
Valsartan
/ adverse effects
Young Adult
angiotension receptor blocker
cardiomyopathy, hypertrophic
randomized controlled trial
Journal
Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
entrez:
10
12
2019
pubmed:
10
12
2019
medline:
17
6
2020
Statut:
ppublish
Résumé
The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progression. We describe the baseline characteristics of the VANISH cohort and compare to previous trials evaluating angiotensin receptor blockers. Applying a randomized, double-blinded, placebo-controlled design, 178 participants with nonobstructive HCM (age, 23.3±10.1 years; 61% men) were randomized in the primary cohort and 34 (age, 16.5±4.9 years; 50% men) in the exploratory cohort of sarcomeric mutation carriers without left ventricular hypertrophy. In the primary cohort, maximal left ventricular wall thickness was 17±4 mm for adults and The VANISH cohort is much larger, younger, less heterogeneous, and has less advanced disease than prior angiotensin receptor blocker trials in HCM. Participants had relatively normal functional capacity and mild HCM features. New York Heart Association functional class II symptoms were associated with older age, more prominent imaging abnormalities, and URL: https://www.clinicaltrials.gov. Unique identifier: NCT01912534.
Sections du résumé
BACKGROUND
The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progression. We describe the baseline characteristics of the VANISH cohort and compare to previous trials evaluating angiotensin receptor blockers.
METHODS
Applying a randomized, double-blinded, placebo-controlled design, 178 participants with nonobstructive HCM (age, 23.3±10.1 years; 61% men) were randomized in the primary cohort and 34 (age, 16.5±4.9 years; 50% men) in the exploratory cohort of sarcomeric mutation carriers without left ventricular hypertrophy.
RESULTS
In the primary cohort, maximal left ventricular wall thickness was 17±4 mm for adults and
CONCLUSIONS
The VANISH cohort is much larger, younger, less heterogeneous, and has less advanced disease than prior angiotensin receptor blocker trials in HCM. Participants had relatively normal functional capacity and mild HCM features. New York Heart Association functional class II symptoms were associated with older age, more prominent imaging abnormalities, and
CLINICAL TRIAL REGISTRATION
URL: https://www.clinicaltrials.gov. Unique identifier: NCT01912534.
Identifiants
pubmed: 31813281
doi: 10.1161/CIRCHEARTFAILURE.119.006231
pmc: PMC7219518
mid: NIHMS1549522
doi:
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Valsartan
80M03YXJ7I
Banques de données
ClinicalTrials.gov
['NCT01912534']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e006231Subventions
Organisme : NHLBI NIH HHS
ID : P20 HL101408
Pays : United States
Organisme : NHLBI NIH HHS
ID : P50 HL112349
Pays : United States
Références
Circulation. 2004 Mar 16;109(10):1284-91
pubmed: 14993121
N Engl J Med. 2008 May 1;358(18):1899-908
pubmed: 18403758
Am J Cardiol. 2005 Dec 1;96(11):1563-7
pubmed: 16310441
Circulation. 2010 Sep 14;122(11):1130-3
pubmed: 20837938
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8
pubmed: 26582918
J Cardiovasc Electrophysiol. 2008 Jan;19(1):104-10
pubmed: 17916152
Am J Cardiol. 2004 Jun 15;93(12):1510-4
pubmed: 15194022
Am Heart J. 2017 May;187:145-155
pubmed: 28454798
Lancet Diabetes Endocrinol. 2015 Feb;3(2):123-31
pubmed: 25533774
Asia Pac J Clin Oncol. 2017 Dec;13(6):423-427
pubmed: 28198155
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Curr Hypertens Rep. 2009 Jun;11(3):167-72
pubmed: 19442324
JACC Cardiovasc Imaging. 2012 Apr;5(4):370-7
pubmed: 22498326
J Thorac Cardiovasc Surg. 2011 Dec;142(6):e153-203
pubmed: 22093723
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Am J Med. 2004 Jan 1;116(1):14-8
pubmed: 14706660
J Clin Invest. 2010 Oct;120(10):3520-9
pubmed: 20811150
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Circulation. 1995 Aug 15;92(4):785-9
pubmed: 7641357
Circulation. 2018 Oct 2;138(14):1387-1398
pubmed: 30297972
Int Heart J. 2007 Nov;48(6):715-24
pubmed: 18160763
Circ J. 2005 Oct;69(10):1244-8
pubmed: 16195625
J Mol Diagn. 2009 Jan;11(1):35-41
pubmed: 19074594
J Appl Physiol (1985). 2005 Aug;99(2):445-57
pubmed: 15557009
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Fundam Clin Pharmacol. 2014 Jun;28(3):249-56
pubmed: 23600722
Circulation. 2001 Feb 13;103(6):789-91
pubmed: 11171784
JACC Heart Fail. 2013 Dec;1(6):480-7
pubmed: 24621999
Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17985-90
pubmed: 17090678